A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo
نویسندگان
چکیده
منابع مشابه
passivity in waiting for godot and endgame: a psychoanalytic reading
this study intends to investigate samuel beckett’s waiting for godot and endgame under the lacanian psychoanalysis. it begins by explaining the most important concepts of lacanian psychoanalysis. the beckettian characters are studied regarding their state of unconscious, and not the state of consciousness as is common in most beckett studies. according to lacan, language plays the sole role in ...
TOFA suppresses ovarian cancer cell growth in vitro and in vivo.
A characteristic feature of cancer cells is the activation of de novo fatty acid synthesis. Acetyl‑CoA carboxylase (ACC) is a key enzyme in fatty acid synthesis, accelerating the reaction that carboxylates cytosolic acetyl‑CoA to form malonyl‑CoA. ACC is highly expressed in several types of human cancer and is important in breast and prostate cancer cell growth. The aim of the present study was...
متن کاملAntitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells
Receptor-tyrosine-kinase-like Orphan Receptor 1 (ROR1) is a tyrosine-protein kinase transmembrane receptor and ROR1 overexpression is associated with a poor prognosis in various cancers, including ovarian cancer. Targeting of ROR1 has been evaluated as a novel cancer therapy strategy. This study developed a novel chimeric anti-ROR1 Fab antibody (named ROR1-cFab) and then assessed the antitumor ...
متن کاملتعیین ارزش غذایی برخی از ضایعات کشاورزی با استفاده از روشهای ,in vitro,in situ in vivo
چکیده ندارد.
15 صفحه اولCInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.
The mitogen-activated protein kinase kinase 1 and 2 signaling pathway is a major component of the RAS (Rat sarcoma)/RAF (Radpidly accelerated fibrosarcoma)/MEK (mitogen-activated protein kinase kinase)/ERKs (Extracellular signal-regulated kinases) signaling axis that regulates tumorigenesis and cancer cell growth. MEK is frequently activated in various cancers that have mutations in the KRAS an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biomedicine & Pharmacotherapy
سال: 2019
ISSN: 0753-3322
DOI: 10.1016/j.biopha.2019.109420